Q901 for Advanced Solid Tumors
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 130 (estimated)
- Sponsor
- Qurient Co., Ltd. · Industry
This trial is looking for people with certain types of advanced cancer. Participants will receive a treatment called Q901 alone or with another drug and will be monitored for its safety and effectiveness.
You may be able to join if
- I have advanced or metastatic cancer that has not responded to treatment.
- I can have my cancer measured.
- I am aged 18 or older.
- I have a life expectancy of at least 3 months.
- I understand the study and sign a consent form.
You may not be able to join if
- I have serious heart problems or had a heart attack in the past 6 months.
- My heart has a significant electrical issue (QT interval).
- I have an active and uncontrolled infection.
- I have a poorly controlled autoimmune or inflammatory disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityMulticenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Loading trial locations…